

Creating the Future of Patient Care

Scientific Program Draft – September 1, 2023

(The Current Sessions and Presentations are in Eastern Standard Time and Subject to Change)

THURSDAY, SEPTEMBER 21, 2023

8:00AM

WELCOME AND INTRODUCTION

Faina Shtern, MD, President and CEO, AdMeTech Foundation

8:15AM

SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION

Moderators:

Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology

Sigrid Carlsson, MD, PhD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden

8:30AM

Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening

8:30AM

Topic 1A: Year in Review: Emerging Data and Advances in Screening: Sigrid Carlsson, MD, PhD, MPH

8:40AM

Q & A

8:42AM

Topic 1B: Overview - Why We Need Organized Screening Programs: Hendrik Van Poppel, MD, European Association of Urology Policy Office Chairman, and Professor, Department of Urology, University Hospitals Leuven, Belgium

8:52AM

Q & A

8:54AM

Topic 1C: Update on PROBASA Trial: Baseline PSA in Young Men (Aged 45 and 50): Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology

9:04AM

Q & A

9:06AM

Topic 1D: PROFILE Study - Early Data on Targeted Screening for Prostate Cancer in Men of African and African Caribbean Ancestry: Jana McHugh, MB, BCh, BAO, Clinical Research Fellow, Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology, Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom

9:16AM

Q & A

9:18AM

Topic 1E: MRI-Based Prostate Cancer Screening in an Era of MCEds: Mark Emberton, MD, Dean, Faculty of Medical Sciences, and Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom

- 9:28AM** Q & A
- 9:30AM** *Topic 1F: Prostate Cancer Screening Practices in Europe:* Monique Roobol, PhD, Professor of Decision Making in Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands
- 9:40AM** Q & A
- 9:42AM** *Topic 1G: Update on IMPACT - Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers and Men with Lynch Syndrome:* Ros Eeles, PhD, FRCP, FRCR, Professor of Oncogenetics, The Institute of Cancer Research, Royal Marsden Hospital, University of London; and Honorary Consultant in Cancer Genetics and Clinical Oncology, National Health Service (NHS) Foundation Trust, London, United Kingdom
- 9:52AM** Q & A
- 9:54AM** *Topic 1H: Clinical Trial of STHLM3 and MRI:* Tobias Nordstrom, MD, PhD, Associate Professor of Urology, Consultant Urologist, Danderyd Hospital, Karolinska Institute, Sweden
- 10:04AM** Q & A
- 10:06AM-10:36AM** *Panel Discussion: "Smart" Prostate Cancer Screening*
- 10:36AM-11:00AM** **COFFEE BREAK**
- 11:00AM** **SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION**
- Moderators:**
- Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
- Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women's Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization
- 11:00AM** *Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling*
- 11:00 AM** *Topic 2A: Current and Emerging Liquid Diagnostics Overview:* E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal
- 11:10AM** Q & A
- 11:12AM-11:34AM** *Panel Discussion: Liquid Biomarkers*
- 11:34AM** *Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies*
- 11:34AM** *Micro-Ultrasound and MRI for Visualization of Prostate Cancer – Sponsored by Exact Imaging:* Wayne Brisbane, MD, Assistant Professor of Urology, UCLA
- 11:46AM** Q & A
- 11:48AM** *PI-RADS Standardization and Risk Assessment- Recent Advances and Future Plans:* Clare Tempany, MB, BAO, BCh
- 11:58AM** Q & A
- 12:00PM** *Quality Improvement American College of Radiology Program in Prostate MRI:* Andrei Purysko, MD, Associate Professor of Radiology, Cleveland Clinic Lerner College of Medicine. Section of Abdominal Imaging and Nuclear Radiology, Imaging Institute and Glickman Urological and Kidney Institute Cleveland Clinic

- 12:10PM** *Multi-modality (MRI+PET) Imaging for Improved Detection of csPC:* David Margel, MD, PhD, Founder, Rabin Medical Center and BRCA clinic, Member, Early Detection Committee at the Cancer War Society
- 12:20PM** Q & A
- 12:24PM** *Optimized 15 min Protocol with Deep Learning Acceleration for Prostate MRI - Are we there yet? Sponsored by Siemens Healthineers:* Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School
- 12:34PM** Q & A
- 12:36PM** *Optimizing MRI Targeted Biopsy – Including Endorectal Imaging for Tumor Localization and In-Bore Biopsy for Tissue Diagnosis:* Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
- 12:46PM** Q & A
- 12:48PM-1:00PM** *Panel Discussion: Imaging Modalities and Targeted Biopsies*
- 1:00PM-1:22PM** **COFFEE BREAK**
- 1:22PM** ***Topic 3: NCCN Guidelines for Early Detection of Prostate Cancer 2022:*** Preston Sprenkle, MD
- 1:32PM** Q & A
- 1:34PM-2:00PM** **General Discussion** – Moderators, Speakers and Mark Katz, MD, Assistant Professor of Surgery, Boston University School of Medicine
- 2:00PM-3:30PM** **LUNCH BREAK**
- 3:30 PM** **SESSION II (PART 1). CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**
- Moderators:**
- Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF
- Baris Turkbey, MD, Senior Clinician, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- 3:40PM** *NCCN Guidelines for Management of Localized Prostate Cancer:* Robert E. Reiter, MD, MBA, Bing Professor in Prostate Cancer; Director, Prostate Cancer Program and Chief, Division of Urologic Oncology; Assistant Dean, Bioentrepreneurship; Department of Urology, David Geffen School of Medicine at UCLA Institute of Urologic Oncology
- 3:50PM** Q & A
- 3:52PM** ***Topic 1: Panel on Multiomics for Prostate Cancer***
- 3:52PM** *Topic 1A: Emerging Advances in Prostate Cancer Diagnostics - Year in Review:* Matthew Cooperberg, MD
- 4:02PM** Q & A
- 4:04PM** *Topic 1B: Genomics - Prognostic and Predictive Markers:* Ashley Ross, MD, PhD, Associate Professor of Urology, Feinberg School of Medicine, Northwestern Medicine, Northwestern Memorial Hospital
- 4:14PM** Q & A
- 4:16PM** *Topic 1C: Integration of Imaging with Histology, Proteomics and Genomics*
- 4:16PM** *Urology Perspective:* JanPhillip Radtke, MD, MBA, Consultant and Assistant Professor of Urology, Department of Urology, Essen University Medical Center and German Cancer Research Center
- 4:26PM** Q & A

- 4:28PM** *MRI*: Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
- 4:38PM** Q & A
- 4:40PM** *Molecular Imaging*: Michael Hofman, MBBS, FRACP, FAANMS, FICIS, PET Modality Lead, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, The University of Melbourne
- 4:50PM** *Proteomics*: Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
- 5:00PM** Q & A
- 5:04PM** *Pathology Overview*: Thomas M. Wheeler, MD, Director of Surgical Pathology and Cytopathology, Sagis Diagnostics; Distinguished Emeritus Professor and Immediate Past Chair, Department of Pathology & Immunology, Baylor College of Medicine
- 5:14PM** Q & A
- 5:16PM-5:30PM** *Panel Discussion: Multiomics*
- 5:30PM – 6:00PM** **GENERAL DISCUSSION**

FRIDAY, SEPTEMBER 22, 2023

8:00AM **SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**

Moderators:

Carlos A. Buchpiguel, MD, PhD, Director of Molecular Imaging and Nuclear Medicine Division; and Full Professor, Department of Radiology and Oncology, São Paulo University School of Medicine, São Paulo -SP, Brazil

Andrei H. Iagaru, MD, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program Stanford University

Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign

Adam Kibel, MD, Chief of Urology, Brigham Health & Dana-Farber Cancer Institute, DiNovi Family Distinguished Chair in Urology, Brigham and Women's Hospital, Elliott Carr Cutler Professor of Surgery, Harvard Medical School

Lalitha K. Shankar, MD, PhD, Chief, Clinical Trials Branch, Cancer Imaging Program, National Cancer Institute

8:10AM *Topic 2: Gleason Grading Has Served Us Well for More than 50 Years, But It Is Time to Start Afresh:* Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center

8:20AM Q & A

8:22AM *Topic 3: Artificial Intelligence for Improving Prostate Cancer Diagnosis and Treatment:* Martin Eklund, PhD, Professor of Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Sweden

8:32AM Q & A

8:34AM *Topic 4: Molecular and Multi-Modality Imaging for Visualization and Staging of the Initial and Recurrent Disease*

8:34AM *Topic 4A: MRI:* Baris Turkbey, MD, Radiologist, National Cancer Institute, National Institutes of Health

8:44AM Q & A

8:46AM *Topic 4B: Molecular and Multi-Modality Imaging - Predictive Value:* Andrei H. Iagaru, MD

- 8:56AM** Q & A
- 8:58AM** *Topic 4C: Construction and Multi-Center Validation of the Radiomics Model for Non-Invasive Identification of Active Surveillance Candidates:* Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China
- 9:08AM** Q & A
- 9:10AM-10:00AM** *Panel Discussion*
- 10:00AM-10:30AM** **COFFEE BREAK**
- 10:30AM** *Topic 5: Integration of Precision Diagnosis and Precision Treatment*
- 10:30AM** *Topic 5A: Integrated Diagnostics (Radiogenomics) and Patient Selection and Monitoring for Active Surveillance, Surgical and Radiation Treatment:* Sanoj Punnen, MD, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Vice Chair of Research, Department of Urology Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine
- 10:40AM** Q & A
- 10:42AM** *Topic 5B: Selection and Outcomes of Image-Guided, Minimally-Invasive Treatment:* Abhinav Sidana, MD, MPH, Associate Professor of Surgery, Director of Urologic Oncology, University of Cincinnati College of Medicine
- 10:52AM** Q & A
- 10:54AM** *Topic 5C: Radiation Treatment:* Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University
- 11:04AM** Q & A
- 11:06AM-11:20AM** *Panel Discussion: Integration of Precision Diagnosis and Treatment*
- 11:20AM-1:00PM** **LUNCH BREAK**
- 1:00PM** **SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER**
- Moderators:**
- David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program
- Steven Finkelstein, MD, DABR, FACRO, Florida Cancer Affiliates, the US Oncology Network; and Board of Chancellors, American College of Radiation Oncology
- Fernando Maluf, MD, PhD, Director of Medical Oncology, Beneficencia Portuguesa; and Member, Steering Committee, Medical Oncology Center, Albert Einstein Hospital, São Paulo, Brazil
- 1:10PM** *Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease*
- 1:10PM** *Topic 1A: International, Multi-Disciplinary Consensus on Treatment of Advanced Prostate Cancer:* Silke Gillissen, MD, Director of the Oncology Institute of Southern Switzerland and Full Professor at USI Università Della Svizzera Italiana, Bellinzona, Ticino, Switzerland
- 1:20PM** Q & A
- 1:22PM** *Topic 1B: Review of the New Standard in Treatment for Oligometastatic and Systemic Disease: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors:* Marc Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; and Special Advisor, Oncologic Drugs Advisory Committee of the FDA

- 1:32PM** Q & A
- 1:34PM** *Topic 1C: Multi-Disciplinary Approach to Advanced Prostate Cancer Care:* Kelvin A. Moses, MD, PhD, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel
- 1:44PM** Q & A
- 1:46PM** *Topic 1D: Radiation Treatment and Its Integration with Precision Diagnostics*
- 1:46PM** *Radiation Therapy Planning Using Advanced Imaging - Pearls and Pitfalls – Sponsored by Blue Earth:* Sean P. Collins MD, PhD, Professor of Radiation Medicine and Director, CyberKnife Prostate Program, Department of Radiation Medicine, Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center
- 1:58PM** *Emerging Advances in Radiation Treatment and Oligometastatic Disease:* Steven Finkelstein, MD, DABR, FACRO
- 2:10PM** Q & A
- 2:14PM** *Topic 1E: Novel Targeted Treatment and Its Integration with Precision Diagnostics:* Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University
- 2:24PM** Q & A
- 2:26PM** *Topic 1F: Precision Diagnostics and Emerging Treatment Strategies:* David Nanus, MD
- 2:36PM** Q & A
- 2:38PM** *Topic 1G: Immunotherapy:* Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment
- 2:48PM** Q & A
- 2:50PM** *Topic 1H: Sequencing of Treatment:* Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors
- 3:00PM** Q & A
- 3:02PM-3:10PM** *Panel Discussion: Standard and Emerging Treatment*
- 3:10PM-3:40PM** **COFFEE BREAK**
- 3:40PM** **Topic 2: Molecular and Multi-Modality Imaging and Theranostics**
- 3:40PM** *Topic 2A: Molecular Imaging for Staging and Treatment Planning, including Patient Eligibility and Selection for LuPSMA Therapy:* Hossein Jadvar, MD, PhD, MPH, MBA, Professor of Radiology, Urology, and Biomedical Engineering, Division of Nuclear Medicine and Molecular Imaging Center, Keck School of Medicine & Viterbi School of Engineering, USC Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California
- 3:50PM** Q & A
- 3:52PM** *Topic 2B: Theranostics*
- 3:52PM** *Overview and Interim Response Biomarkers – Radiologic Perspective:* Louise Emmett, MD, Professor and Director, Department of Theranostics and Nuclear Medicine, St. Vincent Hospital; and Clinical Research Leader, Garvan Institute of Medical Research, Sydney, Australia
- 4:02PM** Q & A
- 4:04PM** *Medical Oncology Perspective:* Philip Kantoff, MD, Past Chairman of Medicine, Memorial Sloan Kettering Cancer Center; and Jerome and Nancy Kohlberg Emeritus Chair in Medicine, Harvard Medical School
- 4:14PM** Q & A

- 4:16PM-4:30PM** *Panel Discussion: Molecular Imaging and Theranostics:* Speakers, Harshad R. Kulkarni, MD, Nuclear Medicine/Theranostics Physician (Germany), Chief Medical Advisor, BAMF Health; and Brandon Mancini, MD, MBA, Medical Director, BAMF Health
- 4:30PM-6:00PM** **General Discussion** – Moderators, Speakers
- 8:00AM** **SATURDAY, SEPTEMBER 23, 2023**
- SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes**
- Moderators:**
- David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
- Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
- Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
- 8:15AM** *Topic 1: Focal Therapy is Now Ready for Prime Time:* Hashim Ahmed, MD, PhD, Professor and Chair, Division of Surgery, Department of Surgery and Cancer, Imperial College London; Honorary Consultant Urological Surgeon, Imperial Urology, Imperial College Healthcare, NHS Trust, United Kingdom
- 8:25AM** Q & A
- 8:27AM** *Topic 2: Clinical and Genomic Implications of MRI Invisibility:* Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation
- 8:37AM** Q & A
- 8:40AM** *Topic 3: Changing Relationship between Active surveillance and Focal Therapy:* Mark Emberton, MD
- 8:50AM** Q & A
- 8:52AM** *Topic 4: Patient Selection - Radiologic Perspective:* John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
- 9:02AM** *Topic 5: Patient Selection for Prostate Cancer Focal Therapy – Urologic Perspective:* Geoffrey Sonn, MD, Associate Professor of Urology and Radiology, Stanford University School of Medicine
- 9:12AM** Q & A
- 9:16AM** *Topic 6: Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging-Based Short and Intermediate Outcomes:* Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
- 9:26AM** Q & A
- 9:28AM** *Topic 7: Machine Learning & Localized Prostate Cancer:* Wayne Brisbane, MD
- 9:38AM** Q & A
- 9:40AM-10:10AM** **COFFEE BREAK**
- 10:10AM** *Topic 8: Combination of Prostate Ablation with Systemic Therapy for Management of Prostate Cancer:* Abhinav Sidana, MD, MPH
- 10:20AM** Q & A
- 10:22AM-11:00AM** *Panel Discussion: Image-Guided Treatment*

11:00AM-
1:00PM

LUNCH BREAK

1:00PM

PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER

Moderators:

Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health

Quoc-Dien Trinh, MD, MBA, Chief of Urology, Brigham and Women's Faulkner Hospital, Co-Director, Dana-Farber/Brigham and Women's Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School

1:00PM

Community-Based and Patient-Centered Approaches to Addressing Racial Inequities in Prostate Cancer: Yaw Nyame, MD, MS, MBA, Assistant Professor, Department of Urology, University of Washington; Program Lead, Office of Community Outreach and Engagement and Affiliate Assistant Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center

1:10PM

Q & A

1:12PM

Risk Assessment in Black Men: Adam B Murphy, MD, MBA, MSCI

1:22PM

Utilization and Disparity Patterns Related to PC Markers: Michael Leapman, MD, MHS, Associate Professor of Urology, Clinical Program Leader, Prostate and Urologic Cancers Program, Yale Cancer Center

1:32PM

Q & A

1:34PM

Creating an Outreach Program to Address Racial Disparities in Prostate Cancer Care: Quoc-Dien Trinh, MD

1:44PM

Q & A

1:46PM

Panel Discussion: Health Disparities

2:00PM-
2:20PM

COFFEE BREAK

2:20PM

PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT

Moderators:

Paul Boutros, PhD, MBA

Arnold C. Cinman, MD, Partner, Tower Urology, Attending Urologist, Cedars-Sinai Medical Center

Masoom Haider, MD, Professor of Radiology, University of Toronto; Senior Clinician Scientist, Lunenfeld Tanenbaum Research Institute; Director, Machine Learning and Radiomics Lab; and Director, Sinai Health System Research MRI, Canada

Michael H. Johnson, MD, Vice Chief of Urology, Washington University, St. Louis

2:20PM

Connected Care and Latest Developments in Prostate Cancer Management: Ilya Gipp, MD, PhD, Chief Medical Officer, Philips, USA

2:30PM

AI and MRI: Masoom Haider, MD

2:40PM

Q & A

2:44PM

Promise of Artificial Intelligence (AI) in Reducing Health Disparities in Prostate Cancer Surveillance, Diagnosis and Prognosis: Rakesh Shiradkar, PhD, Assistant Professor, Biomedical Engineering, Emory University. Member, Winship Cancer Institute

2:54PM

Q & A

**2:56PM-
3:30 PM** *Panel on Quantitative Imaging and its Role in Patient Management: Perspective from the Quantitative Imaging Network, National Cancer Institute*

2:56 pm - Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan Kettering Cancer Center; and Chair, Quantitative Imaging Network of the National Cancer Institute

3:01 pm - Harini Veeraraghavan, PhD, Associate Attending Computer Scientist, Department of Medical Physics, Memorial Sloan Kettering Cancer Center

3:06 pm - Michael Boss, PhD, Director, Imaging Core Laboratory at American College of Radiology

3:11 pm - Lubomir Hadjiyski, PhD, Professor, Department of Radiology, University of Michigan

3:16 pm – 3:30 pm: *Panel Discussion*

3:30PM *Current State of the Art and Vision for the Future:* Paul Boutros, PhD, MBA

3:42PM *Panel Discussion: Bioinformatics, Artificial Intelligence and Machine Learning*

4:10PM **PRESENTATION OF WINNING ABSTRACTS**

Place #1: *Development of Next Generation Extracellular Vesicle Based Urine Tests for Prostate Cancer:* Sandra M. Gaston, PhD, Research Assistant Professor and Director, Molecular Biomarkers Analytic Laboratory, Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

Place #2: *Artificial Intelligence-Based Cancer Mapping to Aid in Prostate Cancer Therapy:* Sakina Mohammed Mota, Ph.D, Data Scientist, Aveda Health, Inc.

Place #3: *Post-hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies to Assess the Impact of Urinary Activity on Interpretation of 18F-flotufolastat PET/CT:* Dr. Rick Hermsen, Department of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

4:30PM **ADJOURN**